



Biocept Inc.  
Investor Relations Department  
5810 Nancy Ridge Drive  
San Diego, CA 92121  
United States

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

#### NASDAQ: BIOC

Last Trade:	1.48
Trade Time:	4:00 PM ET May 23, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	0.74 - 3.39
Volume	8,739

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Biocept, Inc. is a molecular oncology diagnostics company specializing in Circulating Tumor Cells (CTCs) and biomarker analysis, headquartered in San Diego, California. Our mission is to improve outcomes for cancer patients by advancing oncology diagnostics. We utilize patented and innovative technologies to deliver clinically relevant oncology diagnostics to physicians by providing advanced prognostic and predictive assessments for guiding the course of treating patients. Additionally, we offer services to other laboratory testing providers, academic institutions, research organizations... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- May 22, 2017*  
[Biocept Awarded U.S. Patent with Broad Claims for Antibody Capture of Targets of Interest on Any Solid Surface Including CTCs and Other Materials Shed by Solid Tumors into Blood](#)
- May 18, 2017*  
[Biocept's Target Selector Platform Featured in Three Clinical Abstracts at the 2017 American Society of Clinical Oncology Annual Meeting Where Company Plans to Launch New Marketing Campaign](#)
- May 11, 2017*  
[Biocept Reports First Quarter 2017 Financial Results](#)
- May 10, 2017*  
[The Addario Lung Cancer Medical Institute and Biocept Announce Collaboration and Initiation of Landmark ALCMI-009 Liquid Biopsy Clinical Trial in Lung Cancer](#)
- May 3, 2017*  
[Biocept to Release First Quarter 2017 Financial Results and Host Investor Conference Call on May 11, 2017](#)

## Financials [\[ View all \]](#)

- [First Quarter Financial Results](#)
- Mar 28, 2017*  
[Annual Report \(10-K\)](#)
- Mar 30, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- May 15, 2017*  
[Quarterly Report \(10-Q\)](#)
- Nov 10, 2016*  
[Quarterly Report \(10-Q\)](#)
- Aug 5, 2016*  
[Quarterly Report \(10-Q\)](#)